Andrey Boldyrev, CEO of “CardioNova”: “We are delighted that after the preclinical studies, which have shown safety and efficacy of AHRO-001, this clinical trial has started. The successful accomplishment of Phase I/IIa clinical trial can afford the company to move to the next efficacy phase of studies in patients, suffering from cardiovascular diseases”.